Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Humalog Mix25 (Mix25) is an insulin mixture comprising 25% insulin lispro and 75% neutral protamine lispro.
• Type 2 diabetes management often requires optimizing glycemic control in patients inadequately managed with oral agents.

Purpose of the Study:

• To compare the efficacy of Mix25 against maximum-dose glyburide (GB) in improving glycemic control.
• To assess treatment satisfaction and hypoglycemia rates in patients with type 2 diabetes inadequately controlled with GB.

Main Methods:

• A 4-month randomized, parallel, open-label study.
• Patients received either Mix25 twice daily or maximum-dose glyburide (15 mg daily).
• Glycemic control was measured by HbA1c, blood glucose profiles, and hypoglycemia incidence.

Main Results:

• Mix25 significantly reduced HbA1c compared to glyburide (8.5% vs 9.4%, P=0.001).
• Greater reductions in all blood glucose measurements were observed with Mix25.
• Patients reported higher satisfaction with Mix25, despite a significantly higher rate of hypoglycemia (0.30 vs 0.05 events/patient/30 days).

Conclusions:

• Twice-daily Mix25 injections offer improved glycemic control and treatment satisfaction versus maximum-dose glyburide in type 2 diabetes.
• The enhanced efficacy of Mix25 is associated with a predictable increase in hypoglycemia.
• The study provides real-world comparative data, though a double-blind trial in treatment-naive patients might yield different outcomes.